Document text
Principal Investigator: William Messer
Organization: OREGON HEALTH & SCIENCE UNIVERSITY
Fiscal Year: 2022
Award: $44,999
Funding agency: National Institute of Allergy and Infectious Diseases
A cluster of respiratory illness that emerged in December, 2019 in Wuhan China marked the arrival of novel coronavirus Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19. SARS-CoV-2 infection presents with a spectrum of symptoms, ranging from asymptomatic, to malaise, myalgias, and cough. Approximately 15% of patients will go on to develop severe disease consistent with characterized by pneumonia, with hypoxemia and multi-lobar ground glass opacities on chest CT scan. Many of these patients with severe disease will require ICU care, develop Acute Respiratory Distress Syndrome (ARDS), shock, multisystem organ failure, and superinfections. Extra-corporeal membrane oxygenation (ECMO) may be required to sustain life. Preliminary estimates from the US and China find that older age and underlying co-morbidities such as Chronic Obstructive Pulmonary Disease (COPD), ischemic heart disease, diabetes mellitus, and immunosuppression are associated with increase mortality in COVID-19. However, morbidity and mortality may also occur in younger patients. While anti-viral agents are being studied in randomized controlled trials, there is increasing use of off-label host and pathogen-directed therapies outside of controlled clinical trials and with little to no scientific evidence supporting their use. The research proposed here is “a prospective cohort study to assess longitudinal immune responses in hospitalized patients with covid-19.” This study is a multi-site study coordinated through the NIH NIAID Division of Allergy, Immunology, and Transplantation. The study will use immunophenotyping of host factors that have the potential to predict viral clearance or risk of prolonged viral replication and measures associated with clinical decline versus resolution of COVID-19 and its sequelae. These studies are critical for identifying potential targets and timing for host-directed therapeutic interventions. Understanding host immune response kinetics and phenotypes as they relate to clinical illness will assist in prioritizing trials of host-targeted interventions and treatments to limit or mitigate disease progression and recovery from illness. OHSU is participating as one site in this observational multi-site cohort study of hospitalized COVID-19 patients that will prospectively collect clinical, laboratory, and radiographic patient data in coordination with collection of blood samples and respiratory secretions in order to identify immunophenotypic and genomic features of COVID-19 across the spectrum of disease in hospitalized patients. Subjects will subsequently be followed for up to a year post-infection with interval histories and specimen collection and analysis. Results of this research are expected to help to prioritize interventions and/or optimize timing for administration of host-response directed therapeutics
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><21+ years old><ARDS><Ab-mediated immunity><Ab-mediated protection><Aching muscles><Acute><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Address><Adult><Adult ARDS><Adult Human><Adult RDS><Adult Respiratory Distress Syndrome><Aedes><African><Age><Allergy><Antibodies><Antibody immunity><Antibody protection><Antibody titer measurement><Antibody-mediated protection><Antigens><Antiviral Agents><Antiviral Drugs><Antivirals><Attenuated Vaccines><Blood Sample><Blood specimen><Brazil><CAT scan><CDC><COPD><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 virus><COVID19><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 virus><CT X Ray><CT Xray><CT imaging><CT scan><CV-19><CV19><Caring><Cell Body><Cells><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Cessation of life><China><Chronic Obstruction Pulmonary Disease><Chronic Obstructive Lung Disease><Chronic Obstructive Pulmonary Disease><Circulatory Collapse><Clinical><CoV emergence><CoV-2><CoV2><Cohort Studies><Collection><Computed Tomography><Concurrent Studies><Controlled Clinical Trials><Coughing><Country><Cross Sectional Analysis><Cross-Sectional Analyses><Cross-Sectional Studies><Cross-Sectional Survey><Culicidae><Da Nang Lung><Data><Death><Dengue><Development><Diabetes Mellitus><Disease><Disease Frequency Surveys><Disease Outbreaks><Disease Progression><Disorder><Dose><Enrollment><Extracorporeal Membrane Oxygenation><Flavivirus><Fostering><Frequencies><Genomics><Glass><Group B Arbovirus><Heterogeneity><History><Host Factor><Host Factor Protein><Human><Hypersensitivity><Hypoxemia><Immune><Immune response><Immunes><Immunity><Immunologic Factors><Immunologic Subtyping><Immunological Factors><Immunological response><Immunology><Immunophenotyping><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Individual><Infection><Integration Host Factors><Intervention><Intervention Strategies><Ischemic Heart><Ischemic Heart Disease><Ischemic myocardium><Kinetics><Knowledge><Label><Laboratories><Life><Live-attenuated Vaccine><Lobar><Long-Term Effects><Longterm Effects><Mainland China><Malaise><Mass Vaccinations><Measures><Memory B Cell><Memory B-Lymphocyte><Microbial Superinvasion><Mission><Modeling><Modern Man><Morbidity><Morbidity - disease rate><Mosquitoes><Muscle discomfort><Muscle pain><Muscle pain/fibrositis><Muscle sorenesss><Myalgia><Myalgic><Myocardial Ischemia><Myodynia><Myoneuralgia><Myosalgia><NIAID><NIH><Nail plate><Nails><National Institute of Allergy and Infectious Disease><National Institutes of Health><Organ failure><Outbreaks><Patients><Phase 1/2 Clinical Trial><Phase I/II Clinical Trial><Phenotype><Pneumonia><Policies><Prospective Studies><Prospective cohort study><Public Health><Radiography><Randomized Controlled Trials><Recommendation><Recording of previous events><Recovery><Research><Resolution><Risk><Roentgenography><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Shock><Shock Lung><Site><South Africa><South America><Stiff lung><Symptoms><Testing><Therapeutic><Therapeutic Human Experimentation><Therapeutic Intervention><Therapeutic Research><Tomodensitometry><Transplantation><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><United States National Institutes of Health><Vaccination><Vaccine Antigen><Vaccinee><Vaccines><Viral><Viral Antibodies><Viral Burden><Viral Load><Viral Load result><Viral Vaccines><Viremia><Virus><Virus Replication><Wuhan coronavirus><X-Ray CAT Scan><X-Ray Computed Tomography><X-Ray Computerized Tomography><Xray CAT scan><Xray Computed Tomography><Xray computerized tomography><Yellow Fever Vaccine><Yellow fever virus><ZIKA><ZIKV><Zika Virus><adaptive immune response><adulthood><after COVID-19 infection><after SARS-CoV-2 infection><after SARS-CoV2 infection><after severe acute respiratory distress syndrome CoV-2 infection><ages><anti-viral agents><anti-viral antibody><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antibody based detection><antibody detection><antibody titering><antibody-mediated immunity><antiviral antibody><antiviral compound><antiviral medication><antiviral therapeutic><base><burden of disease><burden of illness><cardiac ischemia><catscan><chest CT><chest computed tomography><circulatory shock><co-morbid><co-morbidity><cohort><comorbidity><computed axial tomography><computer tomography><computerized axial tomography><computerized tomography><corona virus disease 2019><corona virus emergence><coronary ischemia><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><coronavirus patient><critical period><detect antibodies><developmental><diabetes><disease burden><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><enroll><following COVID-19 infection><following SARS-CoV-2 infection><following SARS-CoV2 infection><following severe acute respiratory distress syndrome CoV-2 infection><hCoV19><health organization><heart ischemia><host response><hypoxemic><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immunogen><immunogenicity><immunologic substance><immunological substance><immunophenotype><immunoresponse><immunosuppressive activity><immunosuppressive function><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><intervention therapy><interventional strategy><live vaccine><live vaccines><mortality><myocardial ischemia/hypoxia><myocardium ischemia><nCoV><nCoV2><neutralizing antibody><new CoV><new corona virus><new coronavirus><non-contrast CT><non-human primate><noncontrast CT><noncontrast computed tomography><nonhuman primate><novel CoV><novel corona virus><novel coronavirus><pathogen><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><post SARS-CoV-2 infection><pressure><previous COVID-19 infection><previous SARS-CoV-2 infection><previous SARS-CoV2 infection><previous severe acute respiratory distress syndrome CoV-2 infection><prior COVID-19 infection><prior SARS-CoV-2 infection><prior SARS-CoV2 infection><prior severe acute respiratory distress syndrome CoV-2 infection><prospective><prototype><radiologic imaging><radiological imaging><randomized control trial><recruit><respiratory><response><sample collection><secondary analysis><seroconversion><seropositive><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><specimen collection><super infection><superinfection><transplant><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccine against yellow fever><viraemia><viral multiplication><viral replication><viral sepsis><virus multiplication><virusemia><wet lung><years of life lost to disability><years of life lost to disease><yellow fever virus vaccine><zikav>